{"denoms":[{"counts":[{"groupId":"BG000","value":"28"}],"units":"Participants"}],"groups":[{"description":"All participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"BG000","title":"Pomalidomide 5mg Daily"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"23"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"44.9","upperLimit":"61.3","value":"52.5"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"Cisgender male"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Transgender male"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex/Gender, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"Prior systemic therapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"Liposomal doxorubicin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Paclitaxel"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Radiotherapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Immunomodulatory therapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Interferon alpha"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Local therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Kaposi Sarcoma (KS) Therapy","unitOfMeasure":"Participants"}]}